<h4>Introduction</h4>Glucagon receptor agonists (GRAs) are an emerging class of therapies for obesity and type 2 diabetes, demonstrating encouraging metabolic and weight-reducing effects. The gene discussed is GCGR; the disease is obesity disorder.